Clinical Trials Browser

Withdrawn × Hematologic Neoplasms × Rituximab × Clear all

NCT04138875 2022-06-23

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Phase 2 Withdrawn

Other hematologic neoplasm

Infectious Mononucleosis, Hematologic Neoplasms